Clinical trials: Liraglutide
Amyotrophic Lateral Sclerosis
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
This trial adopts a multicenter, randomized, double-blind, placebo-controlled parallel design. This experiment is divided into two groups: the experimental drug group and the placebo group.
- Trial name
- NCT06726577
- Testing
- TP04HN106, Saline
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Talengen Institute of Life Sciences, Shenzhen, P.R. China.
Obesity
Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
The main objective of this study is to assess the safety and tolerability of multiple doses of AMG 598 administered alone or in combination with liraglutide in adults with obesity.
- Trial name
- NCT03757130
- Testing
- AMG 598, Liraglutide
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Amgen
Metabolism and Nutrition Disorder, Obesity
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have…
- Trial name
- NCT00781937
- Testing
- liraglutide
- Where
- 37 sites in United States, Canada
- Volunteers
- 422 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The trial is designed to show the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in subjects with type 2 diabetes.
- Trial name
- NCT00154401
- Testing
- liraglutide
- Where
- 39 sites in Denmark, France and 2 more
- Volunteers
- 177 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Incretin-based Drugs and Pancreatic Cancer
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone in or combination with other anti-diabetic drugs are associated with an increased risk of pancreatic cancer…
- Trial name
- NCT02475499
- Testing
- DPP-4 inhibitors, GLP-1 analogs, Sulfonylureas
- Where
- Canada
- Volunteers
- 886,172 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease
Fibrosis Lessens After Metabolic Surgery
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis
- Trial name
- FLAMES (NCT06374875)
- Testing
- Metabolic surgery, Incretin-Based Therapy
- Where
- 22 sites in United States, Brazil and 11 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Type 1 Diabetes
Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting
Hypothesis: In type 1 diabetes mellitus, in the setting of a closed loop glucose control system: adjunctive therapy with Liraglutide will afford better post-prandial glycemic excursions than insulin mono-therapy.
- Trial name
- NCT01755416
- Testing
- Closed loop with sensor and Insulin, Closed loop with sensor, Insulin and Liraglutide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Albert Einstein College of Medicine
Type 2 Diabetes Mellitus
Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients
Recent studies in rodents show that glucagon-like peptide-1 (GLP-1) analogues protect against diabetic nephropathy. We hypothesise that this is also the case in humans.
- Trial name
- NCT01664676
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 11 people
- Sponsor
- University of Aarhus
Diabetic Kidney Disease
Antiproteinuric Effects of Liraglutide Treatment
The purpose of the study is to determine the effect of Liraglutide on albuminuria in type 2 diabetes.
- Trial name
- LIRALBU (NCT02545738)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 32 people
- Sponsor
- Steno Diabetes Center Copenhagen
Type2 Diabetes
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular…
- Trial name
- ZQL007 (NCT03883412)
- Testing
- Exercise, Liraglutide
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Severe Obesity, Cardiovascular Function
Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity
This randomized controlled trial evaluates the efficacy, safety, metabolic, and cardiovascular effects of liraglutide in children aged 6 to 12 years with severe obesity.
- Conditions
- Severe Obesity, Cardiovascular Function, Liraglutide, Childhood Obesity
- Trial name
- NCT07590219
- Testing
- Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Sao Paulo General Hospital
Diabetes Mellitus, Type 1
Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)
Type 1 diabetes is an autoimmune disease characterized by destruction of pancreatic beta-cells, resulting in absolute deficiency of insulin. Presently there is no known cure.
- Trial name
- NCT03182426
- Testing
- Plerixafor, Alemtuzumab, Anakinra
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University of Alberta
Diabetes, Diabetes Mellitus, Type 2
Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to establish the dose response relationship on glycaemic control of five dose levels of NNC90-1170.
- Trial name
- NCT01509755
- Testing
- liraglutide, glimepiride
- Where
- 29 sites in Denmark, Norway and 2 more
- Volunteers
- 196 people
- Sponsor
- Novo Nordisk A/S
Delirium, Postoperative
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.
- Trial name
- NCT06361238
- Testing
- Liraglutide injection
- Where
- China
- Volunteers
- 260 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Diabetes, Diabetes Mellitus Type 2
A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
This trial is conducted in the United States of America (USA). The aim of the trial is to investigate the efficacy, safety, and tolerability of once-daily subcutaneous (SC) injections of NNC0090-2746 for 12 weeks, as an adjunct…
- Trial name
- NCT02205528
- Testing
- Liraglutide, Metformin, NNC0090-2746
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment…
- Trial name
- NCT00696657
- Testing
- semaglutide, liraglutide
- Where
- 77 sites in Austria, Bulgaria and 12 more
- Volunteers
- 415 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs.
- Trial name
- LIRA-PRIME (NCT02730377)
- Testing
- liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors
- Where
- 232 sites in United States, Canada and 8 more
- Volunteers
- 1,991 people
- Sponsor
- Novo Nordisk A/S
Panhypopituitarism, Craniopharyngioma
The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study
GLP-1 analogs are used as agents in the existing treatment of obesity. However, there are lack of previous reports on the effectiveness and role of GLP-1 analogs in the development of obesity traits in patients with functionally…
- Conditions
- Panhypopituitarism, Craniopharyngioma, Hypothalamic Obesity
- Trial name
- NCT06217848
- Testing
- Saxenda
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital
Diabetes, Diabetes Mellitus, Type 2
Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Japan. The aim of this trial is to assess the safety after multiple s.c. (subcutaneously) doses of liraglutide in Japanese subjects with type 2 diabetes.
- Trial name
- NCT01615978
- Testing
- liraglutide
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with…
- Trial name
- NCT01272232
- Testing
- liraglutide
- Where
- 161 sites in United States, France and 11 more
- Volunteers
- 846 people
- Sponsor
- Novo Nordisk A/S